AB011A3

AB011A3 is a first-in-class monoclonal antibody developed by Aronora that targets the Apple 3 (A3) domain of coagulation Factor XI. By binding to this specific domain, the drug inhibits the function of Factor XI, a key component in the intrinsic pathway of coagulation. This mechanism is intended to prevent and treat thrombosis while potentially minimizing the risk of bleeding compared to traditional anticoagulants, which often target the common pathway of the coagulation cascade. The drug was co-invented by Dr. David Gailani and is currently in preclinical or early development stages as part of Aronora's specialized pipeline of Factor XI inhibitors.